NCT00495612View on ClinicalTrials.gov

A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Asthma

Interventions

DRUG

Omalizumab

Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.

DRUG

Placebo

Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.